Shares of Venus Remedies soared by 8.39% on Thursday, reaching an intraday high of ₹384.95 per share.
The surge followed the announcement that the pharmaceutical company secured an award from UNICEF for its antibiotic product, Ceftriaxone 1 gm, in the Beta Lactam tender.
By 2:50 PM, the shares were trading 7.48% higher at ₹380.85 on the NSE.
Venus Remedies announced that it has received an award from UNICEF for its antibiotic product, Ceftriaxone 1 gm, following its earlier GMP approval from UNICEF. The award highlights the company’s commitment to exceptional quality standards and excellence in healthcare. Ceftriaxone 1 gm has met stringent quality criteria, reinforcing Venus Remedies’ role as a trusted partner in global health initiatives. Ceftriaxone is used to treat bacterial infections.
